PBM
CHRS icon

Propel Bio Management’s Coherus Oncology CHRS Stock Holding History

Propel Bio Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,420,550
Closed -$2.41M – 31
2026
Q1 		$2.41M Buy
+1,420,550
New +$2.52M 1.52% 25

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Propel Bio Management's CHRS Position: Q2 2026 in Review

Propel Bio Management sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 1,420,550 shares — an estimated $2.41M sold.

Propel Bio Management first reported a position in CHRS in Q1 2026 and held it in 1 quarter. The position peaked at $2.41M in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Propel Bio Management reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 1,420,550 Coherus Oncology shares in Q2 2026, an estimated $2.41M.
  • Propel Bio Management first reported a position in Coherus Oncology in Q1 2026 and held it in 1 quarter.
  • Propel Bio Management's Coherus Oncology position peaked at $2.41M in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.